Exagen Inc reports results for the quarter ended March 31 - Earnings Summary

Exagen

05/05/2025 14:32

Exagen Inc XGN.OQ reported a quarterly adjusted loss of 20 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -19 cents.  The mean expectation of six analysts for the quarter was for a loss of 20 cents per share. Wall Street expected results to range from -23 cents to -18 cents per share.

Revenue rose 7.5% to $15.50 million from a year ago; analysts expected $14.54 million.

Exagen Inc's reported EPS for the quarter was a loss of 20 cents​.

The company reported a quarterly loss of $3.75 million.

Exagen Inc shares had risen by 67.7% this quarter and gained 46.8% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 13.1% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the healthcare facilities & services peer group is also "buy"

Wall Street's median 12-month price target for Exagen Inc is $7.00

This summary was machine generated from LSEG data May 5 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.20
-0.20
Met
Dec. 31 2024
-0.26
-0.20
Beat
Sep. 30 2024
-0.29
-0.28
Beat
Jun. 30 2024
-0.34
-0.16
Beat